Loading... Please wait...
Sort by:
  • Multiple Sclerosis: Update Bulletin [May 2017]
    Learn More Multiple Sclerosis: Update Bulletin [May 2017]
    Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus (ocrelizumab,...
  • Market Access Impact: Growth Hormone Deficiency (US) 2017
    Learn More Market Access Impact: Growth Hormone Deficiency (US) 2017
    What stops doctors from prescribing your brand? It may be more than one thing Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of them. According to...
  • Melanoma: KOL Insight: Update Bulletin [May 2017]
    Learn More Melanoma: KOL Insight: Update Bulletin [May 2017]
    This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma announcing that it has withdrawn its New Drug Application (NDA)...
  • Charting MSL Activity and Performance (2017)
    Learn More Charting MSL Activity and Performance (2017)
    A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...
  • Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [May 2017]
    Learn More Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [May 2017]
    Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Coverage includes KOL opinions about the Phase III results...
  • Market Access Impact: Renal Cell Carcinoma (EU5) 2017
    Learn More Market Access Impact: Renal Cell Carcinoma (EU5) 2017
    Eliminating market barriers could help one brand almost double its market share Market barriers have a modest but significant effect on renal cell carcinoma (RCC) prescriptions in the EU5. The brands that can find a way...
  • NSCLC: KOL Insight: Update Bulletin [May 2017]
    Learn More NSCLC: KOL Insight: Update Bulletin [May 2017]
    Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment...
  • Market Access Impact: Renal Cell Carcinoma (US) 2017
    Learn More Market Access Impact: Renal Cell Carcinoma (US) 2017
    Who wins when high costs drag the leading brand down? Market barriers affect nearly a quarter of renal cell carcinoma (RCC) prescriptions in the US. High costs especially are preventing oncologists we surveyed from...
  • NPS+ Asthma/COPD (EU5) 2017
    Learn More NPS+ Asthma/COPD (EU5) 2017
    Is there a loyalty issue for the leading asthma/COPD brands in Europe? With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do...
  • NPS+ Asthma/COPD (US) 2017
    Learn More NPS+ Asthma/COPD (US) 2017
    Is there a loyalty issue for the leading asthma/COPD brands in the US?  With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do...
  • Medical Affairs Reputations: HIV (EU5) 2017
    Learn More Medical Affairs Reputations: HIV (EU5) 2017
    Targeted improvements could help your medical affairs team win over doctors The infectious disease specialists we surveyed say medical affairs teams for 9 major HIV treatments could be doing a better job. They...
  • Medical Affairs Reputations: HIV (US) 2017
    Learn More Medical Affairs Reputations: HIV (US) 2017
    Survey shows medical affairs teams must be more active and provide better information Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those...
  • Real World Data: Meeting Payer Needs
    Learn More Real World Data: Meeting Payer Needs
    How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...
  • AML: KOL Insight: Update Bulletin [May 2017]
    Learn More AML: KOL Insight: Update Bulletin [May 2017]
    This update bulletin  presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include: Novartis receiving US FDA approval for Rydapt (midostaurin)...
  • HNSCC: KOL Insight: Update Bulletin [May 2017]
    Learn More HNSCC: KOL Insight: Update Bulletin [May 2017]
    This edition presents key opinion leader (KOL) views on recent developments in the treatment of head and neck small cell carcinoma (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers...
  • How Payers Want to Work With Pharma
    Learn More How Payers Want to Work With Pharma
    How to effectively engage US and EU payers You’re speaking to payers, but are they listening?  Do you really understand their needs and concerns?  Is your approach to payer negotiations getting your...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved